Marc Machaalani, MD on MAdCAM-1 - Summary - MDSpire

Marc Machaalani, MD on MAdCAM-1

Kidney cancer research at ESMO25: Dana-Farber's Marc Machaalani, MD, shares 3 key takeaways from his presentation on the protein MAdCAM-1 and its ability to predict outcomes in patients with metastatic renal cell carcinoma.

  • November 5, 2025

Share

Objective:

To discuss the prognostic value of MAdCAM-1 in metastatic renal cell carcinoma.

Key Findings:
  • Circulating MAdCAM-1 levels are prognostic of clinical outcomes in metastatic renal cell carcinoma.
  • MAdCAM-1 serves as a dynamic biomarker for tracking gut dysbiosis-driven immune dysregulation.
  • The MAdCAM-1 pathway could be a therapeutic target for microbiota-directed interventions.
Interpretation:

MAdCAM-1 levels can provide insights into patient prognosis and potential treatment strategies.

Limitations:
  • Further research is needed to validate findings across diverse populations.
  • The role of gut microbiota in immune regulation requires more exploration.
Conclusion:

MAdCAM-1 has potential as a biomarker and therapeutic target in treatment-resistant renal cell carcinoma.

Original Source(s)

Marc Machaalani, MD on MAdCAM-1

  • November 5, 2025

Related Content

Fox Chase Cancer Center and Temple Researchers Highlight Need for Molecular Testing in Diagnosing Two Types of Kidney Cancer

Genetic testing may be the most effective way for researchers to distinguish between a rare form of kidney cancer and another that is more common, potentially preventing misdiagnoses, according to a recent study by researchers at Fox Chase Cancer Center and Temple University Hospital.

  • by

  • October 8, 2025

  • 3 min
Renal arterial pseudoaneurysm after robotic-assisted partial nephrectomy: a single-center analysis

International Kidney Cancer Collaboration with Leadership from Philadelphia

Kidney cancer is a growing global health problem, and both clinicians and policymakers need to prepare for a steep rise in the number of cases,” said Alexander Kutikov, MD, FACS, Chair of the Department of Urology at Fox Chase Cancer Center, and senior author of a landmark international study published in European Urology, which demonstrates that if current trends continue, kidney cancer cases could double by 2050

  • by

  • December 2, 2025

  • 3 min